title: Individualized rituximab treatment for neuromyelitis Optica spectrum disorders.
authors.forename: Andrew
authors.initials: A
authors.lastname: McKeon
authors.forename: Sean
authors.initials: S
authors.lastname: Pittock
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology; D051401:Aquaporin 4 / Q000276:immunology / Q000378:metabolism; D001323:Autoantibodies / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D009471:Neuromyelitis Optica / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000276:immunology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D051401:Aquaporin 4; D001323:Autoantibodies; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D000069283:Rituximab